Cancer Letters
Volume 291, Issue 2 , Pages 217-224 , 28 May 2010

Identification of a small molecule inhibitor of serine 276 phosphorylation of the p65 subunit of NF-κB using in silico molecular docking

  • Mary Law
    • ,
  • Patrick Corsino
    • ,
  • Nicole Teoh Parker
    • ,
  • Brian K. Law

      Affiliations

    • Corresponding Author InformationCorresponding author. Address: Department of Pharmacology and Therapeutics, Shands Cancer Center, University of Florida, 1376 Mowry Rd., Rm. 275-G, Gainesville, FL 32610, United States. Tel.: +1 352 273 8167; fax: +1 352 273 8285.

Received 14 May 2009 ,Revised 16 October 2009 ,Accepted 20 October 2009.

References 

  1. Karin M. Nuclear factor-κB in cancer development and progression. Nature. 2006;441:431–436
  2. Chen F, Castranova V. Nuclear factor-κB, an unappreciated tumor suppressor. Cancer Res. 2007;67:11093–11098
  3. Mukhopadhyay T, Roth JA, Maxwell SA. Altered expression of the p50 subunit of the NF kappa B transcription factor complex in non-small cell lung carcinoma. Oncogene. 1995;11:999–1003
  4. Bargou RC, Leng C, Krappmann D, Emmerich R, Mapara MY, Bommert K, et al. High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood. 1996;87:4340–4347
  5. Berger C, Brousset P, McQuain C, Knecht H. Deletion variants within the NF-kappaB activation domain of the LMP1 oncogene in acquired immunodeficiency syndrome-related large cell lymphomas, in prelymphomas and atypical lymphoproliferations. Leukemia Lymphoma. 1997;26:239–250
  6. Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM, et al. Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J. Clin. Invest. 1997;100:2952–2960
  7. Devalaraja MN, Wang DZ, Ballard DW, Richmond A. Elevated constitutive IkappaB kinase activity and IkappaB-alpha phosphorylation in Hs294T melanoma cells lead to increased basal MGSA/GRO-alpha transcription. Cancer Res. 1999;59:1372–1377
  8. Dejardin E, Deregowski V, Chapelier M, Jacobs N, Gielen J, Merville MP, et al. Regulation of NF-kappaB activity by I kappaB-related proteins in adenocarcinoma cells. Oncogene. 1999;18:2567–2577
  9. Chen F, Lu Y, Zhang Z, Vallyathan V, Ding M, Castranova V, et al. Opposite effect of NF-kappa B and c-Jun N-terminal kinase on p53-independent GADD45 induction by arsenite. J. Biol. Chem. 2001;276:11414–11419
  10. Zhong H, Voll RE, Ghosh S. Phosphorylation of NF-kappa B p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Mol. Cell. 1998;1:661–671
  11. Vermeulen L, De Wilde G, Van Damme P, Vanden Berghe W, Haegeman G. Transcriptional activation of the NF-kappaB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1). EMBO J. 2003;22:1313–1324
  12. Anrather J, Racchumi G, Iadecola C. Cis-acting element-specific transcriptional activity of differentially phosphorylated nuclear factor-kappa B. J. Biol. Chem. 2005;280:244–252
  13. Jamaluddin M, Wang S, Boldogh I, Tian B, Brasier AR. TNF-alpha-induced NF-kappaB/RelA Ser(276) phosphorylation and enhanceosome formation is mediated by an ROS-dependent PKAc pathway. Cell Signal. 2007;19:1419–1433
  14. Nowak DE, Tian B, Jamaluddin M, Boldogh I, Vergara LA, Choudhary S, et al. RelA Ser276 phosphorylation is required for activation of a subset of NF-kappaB-dependent genes by recruiting cyclin-dependent kinase9/cyclin T1 complexes. Mol. Cell. Biol. 2008;28:3623–3638
  15. Gilmore TD, Herscovitch M. Inhibitors of NF-kappaB signaling: 785 and counting. Oncogene. 2006;25:6887–6899
  16. Shoichet BK, McGovern SL, Wei B, Irwin JJ. Lead discovery using molecular docking. Curr. Opin. Chem. Biol. 2002;6:439–446
  17. Ofir R, Dwarki VJ, Rashid D, Verma IM. CREB represses transcription of fos promoter: role of phosphorylation. Gene Expression. 1991;1:55–60
  18. Zhong H, SuYang H, Erdjument-Bromage B, Tempst P, Ghosh S. The transcriptional activity of NF-kappaB is regulated by the IkappaB-associated PKAc subunit through a cyclic AMP-independent mechanism. Cell. 1997;89:413–424
  19. Sethi G, Ahn KS, Sandur SK, Lin X, Chaturvedi MM, Aggarwal BB. Indirubin enhances tumor necrosis factor-induced apoptosis through modulation of nuclear factor-κB signaling pathway. J. Biol. Chem. 2006;281:23425–23435
  20. Joo JH, Jetten AM. NF-kappaB-dependent transcriptional activation in lung carcinoma cells by farnesol involved p65/RelA(Ser276) phosphorylation via the MEK-MSK1 signaling pathway. J. Biol. Chem. 2008;283:16391–16399
  21. Makarov SS. NF-kappaB as a therapeutic target in chronic inflammation: recent advances. Mol. Med. Today. 2000;6:441–446
  22. Courtois G, Gilmore TD. Mutations in the NF-κB signaling pathway: implications for human disease. Oncogene. 2006;25:6831–6843
  23. Uwe S. Anti-inflammatory interventions of NF-kappaB signaling: potential applications and risks. Biochem. Pharmacol. 2008;75:1567–1679
  24. Prasad RC, Wang XL, Law BK, Davis B, Green G, Boone B, et al. Identification of genes, including the gene encoding p27Kip1, regulated by serine 276 phosphorylation of the p65 subunit of NF-κB. Cancer Lett. 2009;275:139–149
  25. Chrivia JC, Kwok RP, Lamb N, Hagiwara M, Montiminy MR, Goodman RH. Phosphorylated CREB binds specifically to the nuclear protein CBP. Nature. 1993;365:855–859
  26. Best JL, Amezcua CA, Mayr B, Flechner L, Murawsky CM, Emerson B, et al. Identification of small-molecule antagonists that inhibit an activator-coactivator interaction. Proc. Natl. Acad. Sci. 2004;101:17622–17627
  27. Luca M, Huang S, Gershenwald JE, Singh RK, Reich R, Bar-Eli M. Expression of interleukin-8 by human melanoma cells upregulates MMP-2 activity and increases tumor growth and metastasis. Am. J. Pathol. 1997;151:1105–1113
  28. Xu L, Fidler IJ. Interleukin 8: an autocrine growth factor for human ovarian cancer. Oncol. Res. 2000;12:97–106
  29. Huang S, Mills L, Mian B, Tellez C, McCarty M, Yang XD, et al. Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am. J. Pathol. 2002;161:125–134
  30. B Ancrile B, O’Hayer KM, Counter CM. Oncogenic ras-induced expression of cytokines: a new target of anti-cancer therapeutics. Mol. Interv. 2008;8:22–27
  31. Lin KY, Lu D, Hung CF, Peng S, Huang L, Jie C, et al. Ectopic expression of vascular cell adhesion molecule-1 as a new mechanism for tumor immune evasion. Cancer Res. 2007;67:1832–1841

PII: S0304-3835(09)00637-5

doi: 10.1016/j.canlet.2009.10.015

Cancer Letters
Volume 291, Issue 2 , Pages 217-224 , 28 May 2010

Article Tools

* Image Usage & Resolution